• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    PCA3 and TMPRSS2-ERG gene fusions as diagnostic biomarkers for prostate cancer

    2016-03-24 10:46:02ZhengYangLuYuZheWang
    Chinese Journal of Cancer Research 2016年1期

    Zheng Yang*, Lu Yu*, Zhe Wang

    1State Key Laboratory of Cancer Biology, Department of Pathology, Xi Jing Hospital, Xi’an 710032, China;2The First Cadet Brigade, Fourth Military Medical University, Xi’an 710032, China

    *These authors contributed equally to this work.

    Correspondence to: Prof. Zhe Wang. State Key Laboratory of Cancer Biology, Department of Pathology, Xi Jing Hospital, Fourth Military Medical University, Xi’an 710032, China. Email: zhwang@fmmu.edu.cn.

    ?

    PCA3 and TMPRSS2-ERG gene fusions as diagnostic biomarkers for prostate cancer

    Zheng Yang1,2*, Lu Yu1*, Zhe Wang1

    1State Key Laboratory of Cancer Biology, Department of Pathology, Xi Jing Hospital, Xi’an 710032, China;2The First Cadet Brigade, Fourth Military Medical University, Xi’an 710032, China

    *These authors contributed equally to this work.

    Correspondence to: Prof. Zhe Wang. State Key Laboratory of Cancer Biology, Department of Pathology, Xi Jing Hospital, Fourth Military Medical University, Xi’an 710032, China. Email: zhwang@fmmu.edu.cn.

    Abstract:The incidence of prostate cancer (PCa) is rising steadily among males in many countries. Serum prostate-specific antigen (PSA) is widely applied to clinical diagnosis and screening of PCa. However, the so-called grey area of PSA levels 4.0–10.0 ng/mL has a low specificity of 25–40% resulting in a high rate of negative biopsy and overtreatment. So in order to treat PCa patients in early stage, there is an urgent need for new biomarkers in PCa diagnosis. The PCA3 gene, a non-coding RNA (ncRNA) that is highly expressed in prostate cancer (PCa) cells, has been identified as a molecular biomarkers to detect PCa, of which PCA3 has already under clinical application. PCA3 is strongly overexpressed in malignant prostate tissue compared to benign or normal adjacent one. Newly, PCA3 is considered to be a promising biomarker in clinical diagnosis and targeted therapy. The diagnostic signifi cance of PCA3, however, is awaiting further researches. Moreover, it has been demonstrated recently that TMPRSS2-ERG gene fusion is identifi ed as the predominant genetic change in patients diagnosed with PCa. Recent study revealed that combination of the PCA3 and TMPRSS2-ERG gene fusion test optimizes PCa detection compared with that of single biomarker, which would lead to a considerable reduction of the number of prostate biopsies. In this review, we focused on the potential use of PCA3 and TMPRSS2-ERG gene fusion detection in the diagnosis of PCa.

    Keywords:Prostate; prostate cancer antigen 3 (PCA3); TMPRSS2-ERG gene fusion; prostate cancer (PCa); biomarker

    Submitted Apr 26, 2015. Accepted for publication Jan 19, 2016.

    View this article at: http://dx.doi.org/10.3978/j.issn.1000-9604.2016.01.05

    Introduction

    Prostate cancer (PCa) has become as a leading causes of cancer death in many countries among males (1). In recent year, the incidence of PCa have showed an obvious growth trend in China. PCa is becoming urinary tract malignant tumor that impacts Chinese men’s health seriously.

    As a n invasive testing method, the histopathologic evaluation of prostate biopsies is served as the golden standard for the diagnosis of PCa. At the early stage, PCa does not present with patent clinical manifestation. The decision of prostate biopsies implement relies largely on serum prostate-specific antigen (PSA) testing and digital rectal examination (DRE) (2). The limitations of PSA as PCa early detection biomarker are sound discussed, and the controversy of its use in the screening setting were highlighted recently (3). The so-called grey area of PSA levels 4.0–10.0 ng/mL has a low specificity of 25–40% resulting in a high rate of negative biopsy (4). In addition, DRE is very subjective leading to numerous false positive results and many unnecessary biopsies. Thus, there is an urgent need for new biomarkers in the diagnosis of PCa.

    With significant advances in genetics and cell biology, numerous PCa biomarkers have been found recently. Increasing evidence has shown that long non-coding RNAs, such as pro state cancer antigen 3 (PCA3) might be servedas promising biomarkers in the diagnosis of PCa. PCA3 was initially known as DD3, located on chromosome 9q21-22. The PCA3 gene, widely studied in recent years, is probably one of the first biomarkers which already under clinical application. Highly overexpression of PCA3 in PCa tissue was found to be a potential non-invasively prediction of prostate biopsy which might be a promising biomarker in clinical diagnosis (5). The Clinical has focused mainly on an assay about transcription-mediated amplification (TMA, Progensa PCA3 test). Authoritatively, the assay has been approved by the US Food and Drug Administration (FDA) and is Community European (CE) marked for assessing the risk of PCa in men who has a previous negative biopsy (6).

    One of the earliest genetic variation, ERG oncogene, identifi ed as a transcription factor of ETS family, located on chromosomal band 21q22 is overexpressed in over 50% of PCa (7). Transmembrane protease, serine 2 (TMP RSS2), a prostate-specific and androgen regulated gene, locates very closer to ERG on the same chromosome. It has been identified that the overexpression of ERG in major PCa was driven by fusing with TMPRSS2 (8). In recent studies, TMP RSS2-ERG gene fusion is the pervasive variant in about 40% to 70% PCa (9). Due to various detecting method, it is expected that TMPRSS2-ERG gene fusion might be a promising biomarker of PCa.

    Probably, urine and venous blood specimens after prostate massage is the most easily obtained specimen for biomarkers detection. It could be collected non-invasively and is available in large amount. Urine markers are especially attractive when the prostate in the early stage disease and setting of screening (10). We have searched the literatures by using the key words PCA3, TMPRSS2, ERG, and PCa, and reviewed all the published papers. We focus on the potential value of the PCA3 and TMPRSS2-ERG gene fusion, especially for their ability to calculate patient risk with ever negative biopsy for the occult cancer.

    PCA3: molecular science and clinical use

    PCA3, named as differential display clone 3 (DD3) initially, found by Bus semakers et al. in 1999, was specifically expressed in PCa tissue from 10- to 100-fold in relation to non-neoplastic prostatic surrounding tissue in 53 of 56 patients treated with radical prostatectomy (11). PCA3 is a non-coding RNA located on chromosome 9q21-22, contains a high density of stop codons, whose biological function is not well-known. Recent study suggested that PCA3 modulated the transcriptional activity of androgen receptor target genes which might play a role in the control of PCa cell survival (12).

    Since PCA3 was discovered by Bussemakers et al., various methods of the measurement has developed, such as Progensa TM PCA3 test, which promote the clinical applicability of PCA3 in the diagnosis of PCA. To evaluate the potential usefulness of PCA3 as a diagnostic marker for PCa, a time-resolved fluoresce-based quantitative RT-PCR assay has been developed. Urine specimens were collected after prostate massage. It has been reported that compared with normal prostate tissue, PCA3 overexpression is 66-fold up-regulated in PCa tissue (13). It also suggested that an average 11-fold up-regulation in prostate tissue specimens containing fewer than 10% PCa cells (13), which means that polymerase chain reaction assay can detected a few cancer cells in a background of normal cells, prompted the potential assay of PCA3 in urine.

    In the study accompanying this review, Merola et al. report on PCA3 in PCa and tumor aggressiveness detection on 407 high-risk patients (3). The PCA3 test showed the best diagnostic function when compared with tPSA and f/tPSA, promoting the choice of high-risk patients that may benefit from the operation of a traumatic prostatic biopsy. In addition, the PCA3 test could show a prognostic value, which higher PCA3 score values would relate to greater tumor aggressiveness.

    PCA3 guides the decision making of prostate biopsy

    The golden standard for the diagnosis of PCa is the histopathologic evaluation of prostate biopsy, which is an invasive testing method. The decision of implementing prostate biopsy relies on PSA testing and DRE. Although raised levels of serum PSA are suggestive of PCa, yet, diagnostic confirmation requires a transrectal prostatic needle biopsy, which is an invasive procedure. Still there is the so-called grey area of PSA levels 4.0–10.0 ng/mL has a low specificity of 25–40% resulting in a high rate of negative biopsy (4). Among those previous negative prostate biopsy, 10–35% can be indentified cancer by a systematic repeat prostate biopsy, which result in a high proportion of unnecessary biopsies (14,15). While making a decision of initial or repeat prostate biopsy, the risk of unnecessary biopsy which leads to complication and patient discomfort, pain, anxiety, waste cost have to be taken into consideration. The PCA3 score is the ratio of PCA3 mRNA to PSA mRNA multiplied by 1,000. Many large-scale multicenterclinical studies have confirmed that the PCA3 score can overcome the disadvantages of the low specificity of the traditional PSA test. Recent data suggested that PCA score is correlated with the positive rate of prostate biopsy (16). It showed that when a PCA3 cutoff score of 35 was used during the fi rst prostate biopsy, the sensitivity and specifi city increased to 82.3% and 89.0% respectively. Compared to using PSA, the best PSA cutoff value of sensitivity and specificity showed only 57.4% and 53.8%, the priority of PCA score is obvious (17-20). An European study suggested that the area under the curve (AUC) of PCA3 was 0.761 and 0.65 in initial and repeat prostate biopsy respectively (16). The synthesis of these finding demonstrated that using PCA3 score at guiding both initial and repeat biopsy has priority over PSA testing.

    Some research suggested that PCA3 has a higher diagnostic accuracy, but strength of evidence was insuf fi cient to conclude that PCA3 testing leads to improve health outcome (21).

    PCA3 and Gleason score

    Histologic differentiation of PCa is closely related to the prognosis, biologic behavior, treatments option and patient outcome. Gleason grading system is used to evaluate the prognosis of PCa based on its microscopic appearance (22). The present results indicated a correlation between PCA3 and Gleason score (23). However, some data suggested that there was no diff erence between the migrated Gleason score tumor group and the group of confirmed Gleason score tumors, thus the ability of PCA3 to predict final Gleason score was limited. In addition, a PCA3 score >35 di d not appear in a multivariate analysis as an independent factor of a Gleason score >7. Consequently, it is blurred of the clinical impact of PCA3 and Gleason score correlation is ambiguous (24).

    Although there are some limitations of PCA3 application, it is still considered as a useful clinical tool in the diagnosis of PCa, especially when the viewpoint of combining PCA3 assay with other markers has been raised up, such as TMPRSS2-ERG gene fusion, another biomarker of PCa (25).

    TMPRSS2-ERG gene fusion in PCa

    ERG gene was identified as a transcription factor of ETS family (26,27), which involved in chromosome translocations in Ewing family of tumors as well as in leukemias. In 2005, frequent overexpression of ERG in PCa was observed (28). Later that year, it was discovered that the mechanism underlying this overexpression was the recurrent genomic rearrangement between the fi rst exon(s) of TMPRSS2 and the ERG oncogenes (29). It had been confirmed that The fu sion of TMPRSS2 and ERG genes appeared in nearly 50% of PCa patients (30,31). TMPRSS2 is an androgen-regulated gene that is preferentially expressed in the prostate (32). TMPRSS2 is located on chromosomal band 21q22. ERG maps also 21q22 in the same orientation, at a distance of approximately 3 Mb. The fusion of the androgen- and prostate-specific regulating sequences and first exon(s) of TMPRSS2 to the coding sequences of ERG resulted in the androgen-regulated overexpression of ERG.

    TMPRS S2-ERG gene fusion in the activation oftra nsforming growth factor beta/smads signaling pathway

    Although the specific role of TMPRSS2-ERG fusion in PCa is not well understood, yet ERG-positive patients have a low rate of high Gleason grade, poor diff erentiation compared to ERG-negative patients (33,34). TMPRSS2-ERG gene fusions may be cancer-initiating, and expressed at both RNA and protein levels in PCa stem cells (34,35). It also has been shown that an anti-epileptic drug targets ERG-positive PCa cells through the activation of tumor suppressors and nuclear receptors (36).

    Recent studies found that it might play an important role in the acitivation of Transforming Growth Factor Beta/Smads Signaling Pathway (37). It is well known that TGF-β signaling pathway involved in cell proliferation, differentiation, migration, adhesion, apoptosis, embryonic development, and is even related to human diseases including cardiovascular, fibrosis, reproductive, wounded healing disorders and cancer (38,39). After TGF-β ligand binding to its receptor, R-Smads (receptor-regulated Smads) including Smad2 and Smad3 protein are phosphorylated, and then form a complex by interacted with Smad4. The complex then translocate into nucleus and bind to target genes.

    It is common to find genetic alteration and recurrent gene fusion between ERG and TMPRSS2 on chromosome 21 in prostate. In these PCa cases, ERG gene expression is significantly upregulated by the androgen-responsive promoter of TMPRSS2. Although the role of TMPRSS2-ERG gene fusion protein in PCa is not well understood, recentresults found that over-expression of ERG may be a useful biomarker of PCa diagnosis.

    TMPRSS2-ERG gene fusion in small cell carcinoma (SCC) of PCa

    SCC, accounts for less than 2.0% of de novo PCa, is a rare variant neuroendocrine tumor of the prostate (40). Compared with prostatic adenocarcinoma, which accounts for most PCas, prostatic SCC shows obvious difference in clinicopathologic features. Most prostati c adenocarcinomas hardly have clinical manifestation and can be identifi ed by an increase of PSA. The process of prostatic adenocarcinomas is slow and the metastasis often occurs at advanced stage. Responding well to androgen ablation treatment, patients with prostati c adenocarcinomas can achieve long life expectancy (41).

    On the contrary, patients with prostati c SCC show no increase in PSA. And the disease progresses rapidly with metastasis at very early stage. For the lack of androgen receptor, prostatic SCC shows resistance to androgen ablation (42). SCC can originate in various organs, such as lung, cervix, prostate, urinary bladder, etc., with the lung being the most common origin. As SCCs arising from diff erent organs share similar histologic, immunohistochemical, and ultrastructural features (43-45), it may be difficult to deduce the origin when SCC is observed in the prostate especially after its metastasis. Besides it, most prostatic SCCs lose the prostate-specific immunohistochemical markers, such as prostatic acid phosphatase, PSA, prostate-specific membrane antigen, and protein (44). Therefor e, a specific molecular marker to distinguish the prostatic origin of SCC may be clinically useful.

    Despite the frequent occurrence of ERG gene rearrangements in adenocarcinoma, the incidence of these rearrangements in prostatic SCC is unclear. Recent study found that the presence of ERG rearrangements in nearly half of the prostatic SCCs is a similar rate of rearrangement that found in prostatic acinar carcinomas. Furthermore, the high concordance rate of ERG rearrangement between the SCC and adenocarcinoma components in a given patient supports a common origin for these two subtypes of PCa. The absence of TMPRSS2-ERG gene fusion in bladder or lung SCCs highlighted the utility of detecting TMPRSS2-ERG gene fusion in SCCs of unknown primary for establishing prostatic origin and identified a promising molecular marker for establishing prostatic origin in SCCs of unknown primary (46).

    Evaluation of PCA3 and TMPRSS2- ERG gene fusions as diagnostic biomarkers for PCa

    The gold standard for the diagnosis of (PCa) is based on the histopathologic evaluation of prostate biopsies, an invasive procedure associated with patients’ discomfort, anxiety and severe complications. Because localized PCa often does not present with symptoms, the selection of men qualifying for prostate biopsies relies on serum PSA testing and digital r ectal examination (DRE). However, PSA has a low specifi city resulting in a high negative biopsy rate (47). And DRE is very subjective. A specific biomarker of PCA is required for clinical diagnosis.

    In 2006, the TMPRSS2-ERG gene fusion transcripts were successfully detected in urine samples (48). This urine test had a sensitivity of 37% and a specificity of 93% for the prediction of PCa on prostate biopsy (7). TMPRSS2-ERG had great predictive value to PCA3 and the European Randomised study of Screening for Prostate Cancer (ERSPC) risk calculator parameters for predicting PCa (6).

    Recent st udy shown that both PCA3 and TMPRSS2-ERG fusion had independent additional predictive value for predicting PCa. Recent study suggested that applying this biomarker panel of PCA3 combine with TMPRSS2-ERG fusion to clinical diagnosis could avoid 35% negative prostate biopsies, missing only 10% of the men with PCa with a Gleason score-7 (7). Implementing the novel biomarker panel PCA3 and TMPRSS2-ERG into clinical practice would lead to a considerable reduction of prostate biopsies.

    However, some cohort studies and meta-analysis revealed that TMPRSS2-ERG fusion status was not a strong predictor of PCa recurrence or cancer-specific mortality. The role of TMPRSS2-ERG in PCa pathogenesis and progression is only starting to emerge (49). Recent study proposed prostate health index (PHI) calculated by a mathematical formula combining PSA molecular forms, which also can off er a reduction in unnecessary biopsy (50).

    Conclusions

    Formerly, PCa candidates biopsy selection relies largely on serum PSA testing and digital rectal examination (DRE). However, due to the lack of specificity, new biomarkers of PCa is needed urgently. Unfortunately, PCA3 test also has limitations. For instance, patients with indolent tumors present a low PCA3 score which PCA3 test cannot exclude.

    Since TMPRSS2-ERG gene fusions has been detectedin a significant portion of PCa, it is identified as a potential diagnostic and therapeutic target of PCa, especially in SCC. And recent study showed a great ascendance of biomarker panel combining PCA3 and TMPRSS2-ERG in PCa diagnosis, which may prevail in clinical practice. Therefore, in order to optimize the PCa detection, combining the PCA3 and TMPRSS2-ERG gene fusion test might have applicable diagnostic.

    Acknowledgements

    Funding: This work was supported by the following grants: National Natural Science Foundation of China No. 31571413, 31201037 (to Dr. Yu) and No. 81570180, 81072103 (to Dr. Wang) from the National Natural Science Foundation of China.

    Footnote

    Confl icts of Interest: The authors have no confl icts of interest to declare.

    References

    1. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87-108.

    2. Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 2014;65:124-37.

    3. Merola R, Tomao L, Antenucci A, et al. PCA3 in prostate cancer and tumor aggressiveness detection on 407 highrisk patients: a National Cancer Institute experience. J Exp Clin Cancer Res 2015;34:15.

    4. Roddam AW, Duff y MJ, Hamdy FC, et al. Use of prostate-specifi c antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ ml: systematic review and meta-analysis. Eur Urol 2005;48:386-99; discussion 398-9.

    5. Jung M, Xu C, Spethmann J, et al. Re: Hessels D, Klein Gunnewiek JMT, van Oort I, Karthaus HFM, van Leenders GJL, van Balken B, Kiemeney LA, Witjes JA, Schalken JA. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003;44:8-16. Eur Urol 2004;46:271-2.

    6. Tomlins SA. Urine PCA3 and TMPRSS2:ERG using cancer-specifi c markers to detect cancer. Eur Urol 2014;65:543-5.

    7. Hessels D, Smit FP, Verhaegh GW, et al. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin Cancer Res 2007;13:5103-8.

    8. Tomlins SA, Bjartell A, Chinnaiyan AM, et al. ETS gene fusions in prostate cancer: from discovery to daily clinical practice. Eur Urol 2009;56:275-86.

    9. Perner S, Mosquera JM, Demichelis F, et al. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol 2007;31:882-8.

    10. Locke JA, Black PC. Next generation biomarkers in prostate cancer. Front Biosci (Landmark Ed) 2016;21:328-42.

    11. Bussemakers MJ, van Bokhoven A, Verhaegh GW, et al. DD3: a new prostate-specifi c gene, highly overexpressed in prostate cancer. Cancer Res 1999;59:5975-9.

    12. Ferreira LB, Palumbo A, de Mello KD, et al. PCA3 noncoding RNA is involved in the control of prostatecancer cell survival and modulates androgen receptor signaling. BMC Cancer 2012;12:507.

    13. Hessels D, Klein Gunnewiek JM, van Oort I, et al. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003;44:8-15; discussion 15-6.

    14. Djavan B, Zlotta A, Remzi M, et al. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men. J Urol 2000;163:1144-8; discussion 1148-9.

    15. Roehl KA, Antenor JA, Catalona WJ. Serial biopsy results in prostate cancer screening study. J Urol 2002;167:2435-9.

    16. Deras IL, Aubin SM, Blase A, et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol 2008;179:1587-92.

    17. Ochiai A, Okihara K, Kamoi K, et al. Clinical utility of the prostate cancer gene 3 (PCA3) urine assay in Japanese men undergoing prostate biopsy. BJU Int 2013;111:928-33.

    18. Salagierski M, Mulders P, Schalken JA. Predicting prostate biopsy outcome using a PCA3-based nomogram in a Polish cohort. Anticancer Res 2013;33:553-7.

    19. Pepe P, Aragona F. Prostate cancer detection rate at repeat saturation biopsy: PCPT risk calculator versus PCA3 score versus case-fi nding protocol. Can J Urol 2013;20:6620-4.

    20. Goode RR, Marshall SJ, Duff M, et al. Use of PCA3 in detecting prostate cancer in initial and repeat prostate biopsy patients. Prostate 2013;73:48-53.

    21. Bradley LA, Palomaki GE, Gutman S, et al. Comparative eff ectiveness review: prostate cancer antigen 3 testing forthe diagnosis and management of prostate cancer. J Urol 2013;190:389-98.

    22. Epstein JI, Pound CR, Partin AW, et al. Disease progression following radical prostatectomy in men with Gleason score 7 tumor. J Urol 1998;160:97-100; discussion 101.

    23. Miller K. Words of wisdom. Re: PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. Whitman EJ, Groskopf J, Ali A, et al. J Urol 2008;180:1975-8; discussion 1978-9. Eur Urol 2009;56:218-9.

    24. Durand X, Xylinas E, Radulescu C, et al. The value of urinary prostate cancer gene 3 (PCA3) scores in predicting pathological features at radical prostatectomy. BJU Int 2012;110:43-9.

    25. Leyten GH, Hessels D, Jannink SA, et al. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Eur Urol 2014;65:534-42.

    26. Rao VN, Papas TS, Reddy ES. erg, a human etsrelated gene on chromosome 21: alternative splicing, polyadenylation, and translation. Science 1987;237:635-9. 27. Reddy ES, Rao VN, Papas TS. The erg gene: a human gene related to the ets oncogene. Proc Natl Acad Sci U S A 1987;84:6131-5.

    28. Petrovics G, Liu A, Shaheduzzaman S, et al. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene 2005;24:3847-52.

    29. Tomlins SA, Mehra R, Rhodes DR, et al. TMPRSS2:ETV4 gene fusions defi ne a third molecular subtype of prostate cancer. Cancer Res 2006;66:3396-400.

    30. Furusato B, Gao CL, Ravindranath L, et al. Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer. Mod Pathol 2008;21:67-75.

    31. Shah RB, Chinnaiyan AM. The discovery of common recurrent transmembrane protease serine 2 (TMPRSS2)-erythroblastosis virus E26 transforming sequence (ETS) gene fusions in prostate cancer: significance and clinical implications. Adv Anat Pathol 2009;16:145-53.

    32. Hermans KG, Boormans JL, Gasi D, et al. Overexpression of prostate-specifi c TMPRSS2(exon 0)-ERG fusion transcripts corresponds with favorable prognosis of prostate cancer. Clin Cancer Res 2009;15:6398-403.

    33. Hu Y, Dobi A, Sreenath T, et al. Delineation of TMPRSS2-ERG splice variants in prostate cancer. Clin Cancer Res 2008;14:4719-25.

    34. Klezovitch O, Risk M, Coleman I, et al. A causal role for ERG in neoplastic transformation of prostate epithelium. Proc Natl Acad Sci U S A 2008;105:2105-10.

    35. Polson ES, Lewis JL, Celik H, et al. Monoallelic expression of TMPRSS2/ERG in prostate cancer stem cells. Nat Commun 2013;4:1623.

    36. Fortson WS, Kayarthodi S, Fujimura Y, et al. Histone deacetylase inhibitors, valproic acid and trichostatin-A induce apoptosis and aff ect acetylation status of p53 in ERG-positive prostate cancer cells. Int J Oncol 2011;39:111-9.

    37. Fang J, Xu H, Yang C, et al. Molecular Mechanism of Activation of Transforming Growth Factor Beta/Smads Signaling Pathway in Ets Related Gene-Positive Prostate Cancers. J Pharm Sci Pharmacol 2014;1:82-85.

    38. de Caestecker MP, Piek E, Roberts AB. Role of transforming growth factor-beta signaling in cancer. J Natl Cancer Inst 2000;92:1388-402.

    39. Tian M, Neil JR, Schiemann WP. Transforming growth factor-β and the hallmarks of cancer. Cell Signal 2011;23:951-62.

    40. Palmgren JS, Karavadia SS, Wakefi eld MR. Unusual and underappreciated: small cell carcinoma of the prostate. Semin Oncol 2007;34:22-9.

    41. Wang HT, Yao YH, Li BG, et al. Neuroendocrine Prostate Cancer (NEPC) progressing from conventional prostatic adenocarcinoma: factors associated with time to development of NEPC and survival from NEPC diagnosis-a systematic review and pooled analysis. J Clin Oncol 2014;32:3383-90.

    42. Stein ME, Bernstein Z, Abacioglu U, et al. Small cell (neuroendocrine) carcinoma of the prostate: etiology, diagnosis, prognosis, and therapeutic implications--a retrospective study of 30 patients from the rare cancer network. Am J Med Sci 2008;336:478-88.

    43. Nicholson SA, Beasley MB, Brambilla E, et al. Small cell lung carcinoma (SCLC): a clinicopathologic study of 100 cases with surgical specimens. Am J Surg Pathol 2002;26:1184-97.

    44. Wang W, Epstein JI. Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases. Am J Surg Pathol 2008;32:65-71.

    45. Yao JL, Madeb R, Bourne P, et al. Small cell carcinoma of the prostate: an immunohistochemical study. Am J Surg Pathol 2006;30:705-12.

    46. Lotan TL, Gupta NS, Wang W, et al. ERG gene rearrangements are common in prostatic small cell carcinomas. Mod Pathol 2011;24:820-8.

    47. Stephan C, Schnorr D, Loening SA, et al. Re: RoddamAW, Duff y MJ, Hamdy FC, et al. Use of prostate-specifi c antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA Level of 2-10 ng/ml: systematic review and meta-analysis. Eur Urol 2005;48:386-99. Eur Urol 2005;48:1059-60; author reply 1060-1.

    48. Laxman B, Tomlins SA, Mehra R, et al. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer. Neoplasia 2006;8:885-8.

    49. Pettersson A, Graff RE, Bauer SR, et al. The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis. Cancer Epidemiol Biomarkers Prev 2012;21:1497-509.

    50. Bruzzese D, Mazzarella C, Ferro M, et al. Prostate health index vs percent free prostate-specifi c antigen for prostate cancer detection in men with "gray" prostate-specifi c antigen levels at fi rst biopsy: systematic review and metaanalysis. Transl Res 2014;164:444-51.

    Cite this article as: Yang Z, Yu L, Wang Z. PCA3 and TMPRSS2-ERG gene fusions as diagnostic biomarkers for prostate cancer. Chin J Cancer Res 2016;28(1):65-71. doi: 10.3978/j.issn.1000-9604.2016.01.05

    doi:10.3978/j.issn.1000-9604.2016.01.05

    在线观看美女被高潮喷水网站| 一个人免费看片子| 一个人看视频在线观看www免费| 成年美女黄网站色视频大全免费 | 日本色播在线视频| 久久午夜综合久久蜜桃| 最近的中文字幕免费完整| 99热这里只有是精品50| 国产精品久久久久久久电影| 亚洲精品色激情综合| 99久久综合免费| 欧美成人精品欧美一级黄| 国产伦理片在线播放av一区| 日韩欧美 国产精品| 中国三级夫妇交换| 一级毛片我不卡| 亚洲人成网站在线播| 99国产精品免费福利视频| 最新的欧美精品一区二区| 免费久久久久久久精品成人欧美视频 | 国产伦在线观看视频一区| 久久久亚洲精品成人影院| 亚洲国产欧美在线一区| 人妻少妇偷人精品九色| 亚洲人成网站在线观看播放| 只有这里有精品99| 成人漫画全彩无遮挡| 免费黄色在线免费观看| 成人午夜精彩视频在线观看| 男人舔奶头视频| 大片电影免费在线观看免费| 国产片特级美女逼逼视频| 免费黄频网站在线观看国产| 人妻夜夜爽99麻豆av| 亚洲国产欧美在线一区| 国产精品一区www在线观看| 在线观看一区二区三区激情| 亚洲精品aⅴ在线观看| 国产男人的电影天堂91| 中文乱码字字幕精品一区二区三区| 久久久国产欧美日韩av| 夫妻性生交免费视频一级片| 国产精品秋霞免费鲁丝片| 亚洲欧美日韩卡通动漫| av线在线观看网站| 日本免费在线观看一区| xxx大片免费视频| 欧美 亚洲 国产 日韩一| 国产日韩欧美亚洲二区| 美女脱内裤让男人舔精品视频| 亚洲国产av新网站| 美女cb高潮喷水在线观看| 中文在线观看免费www的网站| 亚洲成人av在线免费| 人人妻人人澡人人看| 少妇猛男粗大的猛烈进出视频| 亚洲国产成人一精品久久久| 99精国产麻豆久久婷婷| 我的女老师完整版在线观看| 国产淫片久久久久久久久| 成人美女网站在线观看视频| 久久免费观看电影| 久久99热这里只频精品6学生| 亚洲av综合色区一区| 国产毛片在线视频| 欧美亚洲 丝袜 人妻 在线| 亚洲精品国产色婷婷电影| 少妇 在线观看| 午夜免费男女啪啪视频观看| 精华霜和精华液先用哪个| 国产黄片视频在线免费观看| 亚洲人成网站在线播| 亚洲成色77777| www.色视频.com| 午夜老司机福利剧场| av在线app专区| 99视频精品全部免费 在线| 最近最新中文字幕免费大全7| 性色avwww在线观看| 丁香六月天网| 亚洲av日韩在线播放| 日本猛色少妇xxxxx猛交久久| 最近2019中文字幕mv第一页| 日韩欧美一区视频在线观看 | av卡一久久| 亚洲国产精品成人久久小说| 99久久人妻综合| 一级毛片aaaaaa免费看小| 日韩熟女老妇一区二区性免费视频| 日日啪夜夜撸| 九色成人免费人妻av| 亚洲婷婷狠狠爱综合网| 另类精品久久| 在线观看一区二区三区激情| av有码第一页| 久久免费观看电影| 亚洲av.av天堂| 在线观看美女被高潮喷水网站| av在线播放精品| 国产片特级美女逼逼视频| 国产欧美日韩一区二区三区在线 | 男人狂女人下面高潮的视频| 大片免费播放器 马上看| 青春草国产在线视频| 精品亚洲成国产av| 欧美人与善性xxx| 岛国毛片在线播放| 高清黄色对白视频在线免费看 | 一本一本综合久久| 国产一区二区在线观看av| 免费观看a级毛片全部| av福利片在线| 成年美女黄网站色视频大全免费 | 最新的欧美精品一区二区| 亚洲第一区二区三区不卡| 日韩欧美 国产精品| 成人国产麻豆网| 18禁裸乳无遮挡动漫免费视频| 校园人妻丝袜中文字幕| 久久韩国三级中文字幕| 人妻少妇偷人精品九色| 亚洲精品乱码久久久v下载方式| 国产午夜精品一二区理论片| 高清午夜精品一区二区三区| av播播在线观看一区| 国产亚洲91精品色在线| 亚洲色图综合在线观看| 最近的中文字幕免费完整| 国产高清三级在线| av有码第一页| 日本色播在线视频| 久久久精品94久久精品| 免费观看的影片在线观看| 伊人久久国产一区二区| 国产在线视频一区二区| 色吧在线观看| 亚洲欧美一区二区三区国产| h视频一区二区三区| 国产精品久久久久久久电影| 777米奇影视久久| 亚洲精品国产av成人精品| 高清毛片免费看| 色5月婷婷丁香| 久久国产精品大桥未久av | 国产在线免费精品| 免费观看a级毛片全部| 搡女人真爽免费视频火全软件| 六月丁香七月| 国内精品宾馆在线| 亚洲av成人精品一区久久| 中文字幕人妻丝袜制服| 国产精品秋霞免费鲁丝片| 国产精品女同一区二区软件| 在现免费观看毛片| 久久婷婷青草| 成人毛片a级毛片在线播放| 一级片'在线观看视频| 精品国产国语对白av| 国产在线一区二区三区精| 99re6热这里在线精品视频| 中文欧美无线码| 色哟哟·www| 下体分泌物呈黄色| 午夜视频国产福利| 久热久热在线精品观看| 亚洲国产日韩一区二区| 深夜a级毛片| 99九九线精品视频在线观看视频| 国产中年淑女户外野战色| 久热这里只有精品99| 国产成人精品无人区| 最近最新中文字幕免费大全7| 王馨瑶露胸无遮挡在线观看| 人妻一区二区av| 久久亚洲国产成人精品v| 婷婷色麻豆天堂久久| 黑人猛操日本美女一级片| 中文乱码字字幕精品一区二区三区| 青春草视频在线免费观看| 高清午夜精品一区二区三区| 我的女老师完整版在线观看| 丰满少妇做爰视频| 久久久久久久国产电影| 两个人免费观看高清视频 | 亚洲成人手机| 三上悠亚av全集在线观看 | 免费大片18禁| 三级国产精品片| 午夜免费男女啪啪视频观看| 亚洲激情五月婷婷啪啪| 国产精品免费大片| 国产精品熟女久久久久浪| 久久久a久久爽久久v久久| 国产熟女欧美一区二区| 日本vs欧美在线观看视频 | 国产熟女欧美一区二区| 日韩大片免费观看网站| 久久99热6这里只有精品| 久久女婷五月综合色啪小说| 亚洲精品国产成人久久av| 久久久久久人妻| 纵有疾风起免费观看全集完整版| 美女内射精品一级片tv| 欧美激情国产日韩精品一区| 黑人猛操日本美女一级片| 久久久久久久国产电影| 国产精品福利在线免费观看| 99久国产av精品国产电影| 精品一品国产午夜福利视频| 边亲边吃奶的免费视频| 最近最新中文字幕免费大全7| 成人漫画全彩无遮挡| 天堂俺去俺来也www色官网| 99久久精品一区二区三区| 天天躁夜夜躁狠狠久久av| 久久久国产一区二区| 热re99久久国产66热| 亚洲精品国产av蜜桃| 亚洲中文av在线| 久久精品久久久久久噜噜老黄| 一区二区三区四区激情视频| 亚洲国产成人一精品久久久| 大香蕉久久网| 哪个播放器可以免费观看大片| 国产综合精华液| 美女视频免费永久观看网站| 国产欧美亚洲国产| 日韩不卡一区二区三区视频在线| 精品国产国语对白av| 乱码一卡2卡4卡精品| 制服丝袜香蕉在线| 亚洲欧洲日产国产| 久久精品夜色国产| 久久毛片免费看一区二区三区| 日韩av在线免费看完整版不卡| 国产综合精华液| 高清毛片免费看| av福利片在线观看| 欧美bdsm另类| 高清不卡的av网站| av线在线观看网站| 人妻制服诱惑在线中文字幕| 蜜臀久久99精品久久宅男| 亚洲内射少妇av| 下体分泌物呈黄色| videos熟女内射| 一个人看视频在线观看www免费| 只有这里有精品99| 久久影院123| 亚洲精品中文字幕在线视频 | 欧美xxⅹ黑人| 日韩制服骚丝袜av| 少妇猛男粗大的猛烈进出视频| 女的被弄到高潮叫床怎么办| 久久鲁丝午夜福利片| 搡女人真爽免费视频火全软件| 性色avwww在线观看| 午夜影院在线不卡| 男的添女的下面高潮视频| 久久ye,这里只有精品| 啦啦啦啦在线视频资源| 九草在线视频观看| 亚洲av男天堂| 老司机亚洲免费影院| 日韩欧美一区视频在线观看 | 久久精品夜色国产| 久久久久久久久久成人| 亚洲av成人精品一二三区| 中文字幕精品免费在线观看视频 | 久久久久网色| 国产熟女欧美一区二区| 国产免费一区二区三区四区乱码| 亚洲中文av在线| 亚洲av电影在线观看一区二区三区| 国产精品麻豆人妻色哟哟久久| 26uuu在线亚洲综合色| 久久精品夜色国产| 亚洲av日韩在线播放| 国产综合精华液| 丝瓜视频免费看黄片| 在线天堂最新版资源| 我的女老师完整版在线观看| 麻豆成人午夜福利视频| 日日摸夜夜添夜夜添av毛片| 成人毛片a级毛片在线播放| 久久ye,这里只有精品| 免费看日本二区| 女性生殖器流出的白浆| 亚洲av福利一区| 日本黄色片子视频| 大香蕉久久网| 少妇人妻一区二区三区视频| 国产女主播在线喷水免费视频网站| 一级二级三级毛片免费看| 中文字幕亚洲精品专区| 午夜福利在线观看免费完整高清在| 2018国产大陆天天弄谢| 国产亚洲一区二区精品| 亚洲成色77777| 91久久精品国产一区二区三区| 成人二区视频| 伦精品一区二区三区| 最黄视频免费看| 91精品伊人久久大香线蕉| 亚洲图色成人| 国产有黄有色有爽视频| 啦啦啦啦在线视频资源| 久久精品熟女亚洲av麻豆精品| 男女边摸边吃奶| 天堂8中文在线网| 久久精品国产亚洲av天美| 免费观看在线日韩| 亚洲欧洲精品一区二区精品久久久 | 99久久精品一区二区三区| 观看av在线不卡| 国产免费一区二区三区四区乱码| 久久久精品免费免费高清| 精华霜和精华液先用哪个| 精品一区二区三区视频在线| 亚洲无线观看免费| 丰满迷人的少妇在线观看| 国产伦精品一区二区三区四那| 自拍欧美九色日韩亚洲蝌蚪91 | 国产欧美另类精品又又久久亚洲欧美| 亚洲不卡免费看| 亚洲天堂av无毛| 狂野欧美激情性bbbbbb| 日韩av在线免费看完整版不卡| 亚洲国产色片| 永久免费av网站大全| 亚洲欧美清纯卡通| 免费观看av网站的网址| 99久国产av精品国产电影| 国产有黄有色有爽视频| 99久久精品国产国产毛片| 插逼视频在线观看| 国产在视频线精品| 高清午夜精品一区二区三区| 欧美 亚洲 国产 日韩一| 九九在线视频观看精品| 我要看黄色一级片免费的| 欧美区成人在线视频| 亚洲成人手机| 九九在线视频观看精品| 王馨瑶露胸无遮挡在线观看| 国产精品人妻久久久久久| 亚洲av男天堂| 久久精品国产自在天天线| 免费观看性生交大片5| videos熟女内射| 亚洲一区二区三区欧美精品| 一区二区三区免费毛片| 秋霞伦理黄片| 成人国产麻豆网| 亚洲精品第二区| 最近中文字幕2019免费版| 欧美少妇被猛烈插入视频| 尾随美女入室| 国产免费一级a男人的天堂| 人人妻人人添人人爽欧美一区卜| 在线观看人妻少妇| 日韩欧美 国产精品| 免费观看无遮挡的男女| 中文在线观看免费www的网站| 国产亚洲5aaaaa淫片| 美女内射精品一级片tv| 少妇被粗大的猛进出69影院 | 亚洲av免费高清在线观看| 色5月婷婷丁香| 国产欧美另类精品又又久久亚洲欧美| 啦啦啦啦在线视频资源| 男女免费视频国产| 亚洲色图综合在线观看| 两个人免费观看高清视频 | 中文在线观看免费www的网站| 婷婷色综合大香蕉| 99热6这里只有精品| 99精国产麻豆久久婷婷| av免费在线看不卡| av又黄又爽大尺度在线免费看| 99热6这里只有精品| 国产精品一区二区在线观看99| 国产视频首页在线观看| 久久久久久人妻| 一级,二级,三级黄色视频| 美女福利国产在线| 蜜桃在线观看..| 免费不卡的大黄色大毛片视频在线观看| 免费看av在线观看网站| 日本-黄色视频高清免费观看| 日本爱情动作片www.在线观看| 在线观看免费视频网站a站| 一区二区av电影网| 国产精品一二三区在线看| 制服丝袜香蕉在线| 91精品伊人久久大香线蕉| 日韩在线高清观看一区二区三区| 成人国产av品久久久| kizo精华| 青青草视频在线视频观看| 国产精品99久久久久久久久| 亚洲,一卡二卡三卡| 女性生殖器流出的白浆| 成人无遮挡网站| 精品国产一区二区三区久久久樱花| 一本久久精品| 国产有黄有色有爽视频| 下体分泌物呈黄色| 亚洲精品,欧美精品| 男人狂女人下面高潮的视频| 欧美bdsm另类| 丝袜喷水一区| 亚洲欧洲日产国产| 欧美+日韩+精品| 亚洲,一卡二卡三卡| 亚洲成色77777| 国产在视频线精品| 22中文网久久字幕| 免费看av在线观看网站| 日韩不卡一区二区三区视频在线| 少妇精品久久久久久久| 丰满乱子伦码专区| 国产精品99久久久久久久久| 嫩草影院入口| 我的老师免费观看完整版| 国产成人aa在线观看| 蜜臀久久99精品久久宅男| 男人狂女人下面高潮的视频| 亚洲伊人久久精品综合| 日韩视频在线欧美| 久久影院123| 国产在线视频一区二区| 最后的刺客免费高清国语| 国产精品一区二区性色av| 国产美女午夜福利| 亚洲精品,欧美精品| 18禁动态无遮挡网站| 极品人妻少妇av视频| 国产日韩欧美在线精品| 国产精品一区二区在线不卡| 国产精品一区二区三区四区免费观看| 亚洲欧美清纯卡通| av天堂中文字幕网| 久久综合国产亚洲精品| 久久久久国产精品人妻一区二区| 如何舔出高潮| 日韩av在线免费看完整版不卡| 亚洲欧美清纯卡通| 精品酒店卫生间| 我要看日韩黄色一级片| 成人美女网站在线观看视频| 精品一区二区免费观看| 国产一级毛片在线| 国产极品天堂在线| 亚洲国产色片| 男女免费视频国产| 高清欧美精品videossex| 成人亚洲精品一区在线观看| 久久精品久久精品一区二区三区| 午夜免费男女啪啪视频观看| 秋霞在线观看毛片| 免费人妻精品一区二区三区视频| 自线自在国产av| 亚洲自偷自拍三级| 中文资源天堂在线| 少妇猛男粗大的猛烈进出视频| 夜夜看夜夜爽夜夜摸| 国产美女午夜福利| 久久精品国产自在天天线| av在线app专区| 日本猛色少妇xxxxx猛交久久| 人妻一区二区av| 99久久综合免费| 两个人的视频大全免费| 亚洲成人一二三区av| 搡女人真爽免费视频火全软件| 日本欧美视频一区| 成人18禁高潮啪啪吃奶动态图 | 在线播放无遮挡| 一二三四中文在线观看免费高清| 大话2 男鬼变身卡| 久久精品久久久久久久性| 最新中文字幕久久久久| 大又大粗又爽又黄少妇毛片口| 噜噜噜噜噜久久久久久91| av有码第一页| 国产淫片久久久久久久久| 亚洲美女黄色视频免费看| 高清在线视频一区二区三区| 一级毛片电影观看| 九草在线视频观看| 国产老妇伦熟女老妇高清| 街头女战士在线观看网站| 日日啪夜夜爽| 精品一区在线观看国产| h日本视频在线播放| 老司机亚洲免费影院| 国产黄频视频在线观看| 涩涩av久久男人的天堂| 狂野欧美激情性xxxx在线观看| 五月开心婷婷网| 99久国产av精品国产电影| 自拍偷自拍亚洲精品老妇| 亚洲国产精品国产精品| 欧美国产精品一级二级三级 | 女性被躁到高潮视频| 国产精品成人在线| 亚洲图色成人| 丰满乱子伦码专区| 人人妻人人澡人人爽人人夜夜| 精品一区二区三区视频在线| 观看av在线不卡| 欧美一级a爱片免费观看看| 欧美日韩视频高清一区二区三区二| 插逼视频在线观看| 久久99热6这里只有精品| 美女国产视频在线观看| 18+在线观看网站| 好男人视频免费观看在线| 久久免费观看电影| 亚洲不卡免费看| 夫妻午夜视频| 亚洲成色77777| 久久精品夜色国产| www.色视频.com| 国产又色又爽无遮挡免| 欧美日韩国产mv在线观看视频| 亚洲一区二区三区欧美精品| 久久精品国产鲁丝片午夜精品| 国产亚洲午夜精品一区二区久久| 精品酒店卫生间| 亚洲欧美中文字幕日韩二区| 免费播放大片免费观看视频在线观看| 久热这里只有精品99| 日本爱情动作片www.在线观看| 国产免费福利视频在线观看| 国产精品蜜桃在线观看| 国产精品免费大片| 久久久久久久久久久免费av| 少妇人妻精品综合一区二区| 美女国产视频在线观看| 日日摸夜夜添夜夜添av毛片| 春色校园在线视频观看| 少妇人妻一区二区三区视频| 国产成人精品一,二区| 欧美日韩视频高清一区二区三区二| 精品熟女少妇av免费看| 亚洲国产精品成人久久小说| 最近中文字幕2019免费版| 美女主播在线视频| 国国产精品蜜臀av免费| 午夜精品国产一区二区电影| av在线观看视频网站免费| 美女视频免费永久观看网站| 免费观看a级毛片全部| 亚洲国产成人一精品久久久| 草草在线视频免费看| 十八禁高潮呻吟视频 | 免费看av在线观看网站| 久久精品久久久久久噜噜老黄| 十八禁高潮呻吟视频 | 男女无遮挡免费网站观看| 91久久精品国产一区二区三区| 亚洲无线观看免费| 日日摸夜夜添夜夜爱| 人体艺术视频欧美日本| 国产老妇伦熟女老妇高清| 亚洲av中文av极速乱| 丝袜在线中文字幕| 一区二区av电影网| 午夜影院在线不卡| 伦理电影免费视频| 黄色配什么色好看| 人妻人人澡人人爽人人| 国产女主播在线喷水免费视频网站| 建设人人有责人人尽责人人享有的| 又大又黄又爽视频免费| 日本91视频免费播放| 综合色丁香网| 亚洲av欧美aⅴ国产| 久久精品国产亚洲av天美| 国产日韩一区二区三区精品不卡 | 国产精品福利在线免费观看| 亚洲第一av免费看| 日日爽夜夜爽网站| 国产黄色免费在线视频| 欧美精品高潮呻吟av久久| 国产av国产精品国产| 日韩一本色道免费dvd| 丁香六月天网| 一区二区三区四区激情视频| 亚洲精品视频女| 少妇精品久久久久久久| 日日摸夜夜添夜夜爱| 汤姆久久久久久久影院中文字幕| 国产成人精品一,二区| 在线观看免费高清a一片| 蜜臀久久99精品久久宅男| 日本欧美视频一区| 嫩草影院入口| 91aial.com中文字幕在线观看| 亚洲丝袜综合中文字幕| 亚洲国产最新在线播放| 哪个播放器可以免费观看大片| 国产av一区二区精品久久| 日韩免费高清中文字幕av| 婷婷色综合大香蕉| 欧美高清成人免费视频www| 国产精品嫩草影院av在线观看| 一区二区av电影网| 欧美人与善性xxx| 欧美精品亚洲一区二区| 一本色道久久久久久精品综合| av有码第一页| 国产69精品久久久久777片|